jetcityimage/iStock Editorial via Getty Images
- The European Medicines (EMA) announced Friday that Eli Lilly (NYSE:LLY) has requested a reevaluation of a recent decision in which an expert panel of the agency denied marketing authorization for the company’s Alzheimer’s therapy Kisunla (donanemab).
- The EMA’s Committee for